Studies on forgoing treatment often ignore treatments that are continued until death.
To investigate how often specific treatments are withdrawn or withheld before death and to describe the associated patient, physician, and care characteristics.
National mortality follow-back study in Switzerland in 2013/2014 using a standardized survey to collect information on the patient’s end of life and demographics on the physician.
A random sample of adults who died non-suddenly without an external cause and who had met the physician completing the survey (N = 3051).
Any of nine specific treatments was continued until death, withdrawn, or withheld.
In 2242 cases (84%), at least one treatment was either continued until death or withheld or withdrawn. The most common treatment was artificial hydration, which was continued in 23%, withdrawn in 4%, and withheld in 22% of all cases. The other eight treatments were withdrawn or withheld in 70–94% of applicable cases. The impact of physician characteristics was limited, but artificial hydration, antibiotics, artificial nutrition, and ventilator therapy were more likely to be withheld at home and in nursing homes than in the hospitals.
Large differences exist between care settings in whether treatments are continued, withdrawn, or withheld, indicating the different availability of treatment options or different philosophies of care. While certain patient groups are more likely to have treatment withheld rather than attempted, neither patient nor physician characteristics impact the decision to continue or withdraw treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The data and the survey tool are available from the authors on request. The survey tool has been published as supplementary material with Ziegler et al. (2018).20
Cheung MC, Earle CC, Rangrej J, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015;121(18):3307–15.
Wright AA, Keating NL, Ayanian JZ, et al. Family perspectives on aggressive cancer care near the end of life. Jama. 2016;315(3):284–292.
Giannini A, Pessina A, Tacchi EM. End-of-life decisions in intensive care units: attitudes of physicians in an Italian urban setting. Intensive Care Medicine. 2003;29(11):1902–1910.
Groenewoud JH, van der Heide A, Kester JGC, de Graaff CLM, van der Wal G, van der Maas P. A nationwide study of decisions to forgo life-sustaining treatment in Dutch medical practice. Arch Intern Med. 2000;160(3):357–363.
Welie JVM, ten Have HAMJ. The ethics of forgoing life-sustaining treatment: theoretical considerations and clinical decision making. Multidisciplinary Respiratory Medicine. 2014;9:14.
Pereira SM, Pasman HR, van der Heide A, van Delden JJ, Onwuteaka-Philipsen BD. Old age and forgoing treatment: a nationwide mortality follow-back study in the Netherlands. Journal of medical ethics. 2015;41:766–770.
van Wijmen MP, Pasman HR, Widdershoven GA, Onwuteaka-Philipsen BD. Continuing or forgoing treatment at the end of life? Preferences of the general public and people with an advance directive. Journal of medical ethics. 2015;41:599–606.
Chambaere K, Cohen J, Robijn L, Bailey SK, Deliens L. End-of-Life Decisions in Individuals Dying with Dementia in Belgium. Journal of the American Geriatrics Society. 2015;63(2):290–296.
Bosshard G, Nilstun T, Bilsen J, et al. Forgoing treatment at the end of life in 6 European countries. Arch Intern Med. 2005;165(4):401–407.
Schmid M, Zellweger U, Bosshard G, Bopp M. Medical end-of-life decisions in Switzerland 2001 and 2013: Who is involved and how does the decision-making capacity of the patient impact. Swiss Med Wkly. 2016;146:w14307.
Bosshard G, Zellweger U, Bopp M, Schmid M, Hurst SA, Puhan MA, Faisst K. Medical end-of-life practices in Switzerland: A comparison of 2001 and 2013. JAMA internal medicine. 2016;176(4):555–556.
Melltorp G, Nilstun T. The difference between withholding and withdrawing life-sustaining treatment. Intensive Care Med. 1997;23(12):1264–1267.
Rydvall A, Lynöe N. Witholding and withdrawing life-sustaining treatment: a comparative study of the ethical reasoning of physicians and the general public. Critical Care. 2008;12:R13.
Swiss Academy of Medical Sciences (SAMS). Management of dying and death. 2018. Available from: https://www.samw.ch/en/Ethics/Ethics-in-end-of-life-care/Guidelines-management-dying-death.html
Thomson S, Osborn R, Squires D, Reed SJ. International profiles of health care systems 2011: Australia, Canada, Denmark, England, France, Germany, Iceland, Italy, Japan, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United States. Commonwealth Fund pub. 1857
Miccinesi G, Fischer S, Paci E, et al. Physicians’ attitudes towards end-of-life decisions: a comparison between seven countries. Soc Sci Med 2005;60:1961–1974.
Onwuteaka-Philipsen BD, Fischer S, Cartwright C, et al. End-of-life decision making in Europe and Australia. A physician survey. Arch Intern Med 2006;166:921–929.
Escher M, Perneger TV, Rudaz S, Dayer P, Perrier A. Impact of advance directives and a health care proxy on doctors’ decisions: a randomized trial. Journal of pain and symptom management. 2014 Jan 1;47(1):1–1.
Silveira MJ, Wiitala W, Piette J. Advance directive completion by elderly Americans: a decade of change. Journal of the American Geriatrics Society. 2014 Apr;62(4):706–10.
Ziegler S, Schmid M, Bopp M, Bosshard G, Puhan MA. Using sedative substances until death: A mortality follow-back study on the role of healthcare settings. Pall Med 2019;33(2):213–220.
West E, Costantini M, Pasman HR, Onwuteaka-Philipsen B. A comparison of drugs and procedures of care in the Italian hospice and hospital settings: the final three days of life for cancer patients. BMC health services research. 2014;14(1):496.
Stroka, Magdalena A. Drug overprescription in nursing homes: an empirical evaluation of administrative data. The European Journal of Health Economics. 2016;17(3): 257–267.
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? Journal of Clinical Oncology. 2008 Aug 10;26(23):3860.
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI. Chemotherapy use, performance status, and quality of life at the end of life. JAMA oncology. 2015 Sep 1;1(6):778–84.
Druml C, Ballmer PE, Druml W, et al. ESPEN guideline on ethical aspects of artificial nutrition and hydration. Clinical Nutrition. 2016;35(3):545–556.
Bükki J, Unterpaul T, Nübling G, Jox RJ, Lorenzl S. Decision making at the end of life—cancer patients’ and their caregivers’ views on artificial nutrition and hydration. Supportive Care in Cancer. 2014;22(12):3287–3299.
Morita Y, Shima Y, Adachi I. Attitiudes of Japanese physicians toward terminal dehydration: A nationwide survey. Journal of Clinical Oncology. 2002;20(24):4699–4704.
Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliative medicine. 2014;28(8):1000–1025.
De Vleminck A, Pardon K, Beernaert K, Deschepper R, Houttekier D, Van Audenhove C, Deliens L, Vander Stichele R. Barriers to advance care planning in cancer, heart failure and dementia patients: a focus group study on general practitioners' views and experiences. PloS one. 2014;9(1):e84905.
Rietjens JA, Deschepper R, Pasman R, Deliens L. Medical end-of-life decisions: does its use differ in vulnerable patient groups? A systematic review and meta-analysis. Soc Sci Med. 2012;74(8):1282–1287.
Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. Jama. 2013 Aug 28;310(8):797–8.
We thank the Swiss Federal Statistical Office for having sampled deaths for our study and the Swiss Academy of Medical Sciences (SAMS) for ensuring the anonymity of the questionnaires. We are indebted to the many physicians who participated in the study and filled in the questionnaires.
Further members of the Swiss Medical End-of-Life Decisions Study Group are as follows: Karin Faisst (St. Gallen), Felix Gutzwiller (Zurich), Samia Hurst (Geneva), Christoph Junker (Neuchâtel), Milo Alan Puhan (Zurich), Margareta Schmid (Zurich), and Sarah Ziegler (Zurich).
This study was funded by the Swiss National Science Foundation (grant 406740-139309, National Research Program 67 ‘End-of-Life’) and the Palliative Care Research funding program of the Swiss Academy of Medical Sciences; the Gottfried and Julia Bangerter-Rhyner Foundation; and the Stanley Thomas Johnson Foundation (grant PC 03/16).
Consent from the patient was waived by the Zurich Cantonal Ethics Committee (KEK-StV No. 23/13).
Conflict of Interest
The authors declare that they do not have a conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Penders, Y.W.H., Bopp, M., Zellweger, U. et al. Continuing, Withdrawing, and Withholding Medical Treatment at the End of Life and Associated Characteristics: a Mortality Follow-back Study. J GEN INTERN MED 35, 126–132 (2020). https://doi.org/10.1007/s11606-019-05344-5
- palliative care
- end-of-life decisions
- withholding treatment
- medical decision-making